UOC
ACHN

UBS O'Connor’s Achillion Pharmaceuticals ACHN Stock Holding History

UBS O'Connor’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-51,000
Closed -$417K – 606
2013
Q2 		$417K Buy
+51,000
New +$389K 0.01% 424

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS O'Connor's ACHN Position: Q3 2013 in Review

UBS O'Connor sold out of Achillion Pharmaceuticals (ACHN) in Q3 2013, closing a stake of 51,000 shares — an estimated $417K sold.

UBS O'Connor first reported a position in ACHN in Q2 2013 and held it in 1 quarter. The position peaked at $417K in Q2 2013. 102 funds tracked by Wall St. Rank hold ACHN as of Q3 2013.

  • UBS O'Connor reported no remaining Achillion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • UBS O'Connor sold 51,000 Achillion Pharmaceuticals shares in Q3 2013, an estimated $417K.
  • UBS O'Connor first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • UBS O'Connor's Achillion Pharmaceuticals position peaked at $417K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2013.

Based on UBS O'Connor's 13F filing for Q3 2013, filed 14 Nov 2013.